Drug Trial Radar · NCT07044297
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
4,390
Actual
Start
Jul 31, 2025
Primary completion
Jul 22, 2027
Study completion Jul 22, 2027
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jun 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: * If taking MK-8527 once a month works to prevent HIV-1 infection as well as or better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day * About the safety of MK-8527 and if people tolerate it
Conditions
- Human Immunodeficiency Virus (HIV)
- HIV Pre-Exposure Prophylaxis
Interventions
MK-8527Drug
Oral tablet
FTC/TDFDrug
Oral tablet
Placebo to MK-8527Drug
Placebo tablet matched to MK-8527
Placebo to FTC/TDFDrug
Placebo tablet matched to FTC/TDF
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adjudicated Human Immunodeficiency Virus Type 1 (HIV-1) InfectionTime frame: Up to approximately 2 years
- Number of Participants Who Experience At Least One Adverse Event (AE)Time frame: Up to approximately 2 years
- Number of Participants Who Discontinue Study Intervention Due to an AETime frame: Up to approximately 2 years
Locations
81 sites in 16 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham-UAB 1917 Research Clinic ( Site 0006)
Birmingham, Alabama
USA Health University Hospitals ( Site 0020)
Mobile, Alabama
UCLA Center for Clinical AIDS Research and Education ( Site 0004)
Los Angeles, California
Bridge HIV - San Francisco Department of Public Health ( Site 0001)
San Francisco, California
Whitman-Walker Institute ( Site 0016)
Washington D.C., District of Columbia
University of Miami RAPID Research ( Site 0003)
Miami, Florida
Orlando Immunology Center ( Site 0021)
Orlando, Florida
Hope Clinic of the Emory Vaccine Center ( Site 0009)
Decatur, Georgia
University of Illinois Chicago ( Site 0027)
Chicago, Illinois
University Medical Center New Orleans ( Site 0024)
New Orleans, Louisiana
Open Arms Healthcare Center ( Site 0025)
Jackson, Mississippi
Rutgers New Jersey Medical School ( Site 0010)
Newark, New Jersey
Montefiore Medical Center ( Site 0017)
The Bronx, New York
NC TraCS Institute - CTRC; University of North Carolina at Chapel Hill ( Site 0008)
Chapel Hill, North Carolina
Regional Center for Infectious Diseases ( Site 0018)
Greensboro, North Carolina
Philadelphia Fight Community Health Centers ( Site 0011)
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center-Division of Infectious Diseases ( Site 0022)
Pittsburgh, Pennsylvania
Prisma Health Richland Hospital-Clinical Research Unit ( Site 0007)
Columbia, South Carolina
St. Jude Children's Research Hospital ( Site 0026)
Memphis, Tennessee
Meharry Medical College ( Site 0013)
Nashville, Tennessee
Central Texas Clinical Research ( Site 0014)
Austin, Texas
Saint Hope Foundation, Inc. ( Site 0015)
Bellaire, Texas
Fred Hutchinson Cancer Center - The Seattle HIV Vaccine Trials Unit ( Site 0002)
Seattle, Washington
Fundación IDEAA ( Site 0351)
Buenos Aires, Argentina
Centro de Estudios Infectológicos S.A. ( Site 0357)
CABA, Buenos Aires, Argentina
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada ( Site 0352)
CABA, Buenos Aires, Argentina
Fundación Huésped ( Site 0350)
CABA, Buenos Aires, Argentina
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0353)
Mar del Plata, Buenos Aires, Argentina
Instituto Nacional de Infectologia Evandro Chagas ( Site 0407)
Rio de Janeiro, Brazil
Fundaçao de Medicina Tropical Doutor Heitor Vieira Dourado ( Site 0412)
Manaus, Amazonas, Brazil
Obras Sociais Irma Dulce ( Site 0406)
Salvador, Estado de Bahia, Brazil
School of Medicine Federal University of Minas Gerais ( Site 0417)
Belo Horizonte, Minas Gerais, Brazil
Hospital Geral de Nova Iguacu ( Site 0411)
Nova Iguaçu, Rio de Janeiro, Brazil
Ricardo Diaz Scientific Solutions ( Site 0402)
São Paulo, São Paulo, Brazil
Centro de Referência e Treinamento DST/AIDS ( Site 0400)
São Paulo, São Paulo, Brazil
Hospital das Clinicas FMUSP ( Site 0401)
São Paulo, São Paulo, Brazil
Hospital Dr. Hernán Henríquez Aravena ( Site 0451)
Temuco, Araucania, Chile
Universidad San Sebastian - Providencia ( Site 0454)
Santiago, Region M. de Santiago, Chile
Universidad de Chile - Hospital Clínico Universidad de Chile-Inmunologia Alergia y VIH ( Site 0450)
Santiago, Region M. de Santiago, Chile
IPS SURA San Diego ( Site 0500)
Medellín, Antioquia, Colombia
Showing 40 of 81 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.